Neurocrine Biosciences, Inc. (NBIX)
133.50
+2.36
(+1.80%)
USD |
NASDAQ |
Mar 04, 16:00
133.41
-0.09
(-0.07%)
After-Hours: 17:32
Neurocrine Biosciences Research and Development Expense (Annual) : 1.016B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Glaukos Corp. | 150.61M |
| Edgewise Therapeutics, Inc. | 149.30M |
| Nuvalent, Inc. | 306.97M |
| Marker Therapeutics, Inc. | 13.47M |
| CapsoVision, Inc. | 15.12M |